Author

AM Charpentier

Observed name: A-M Charpentier

Institutions: Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal

Observed institutions: Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal

OpenAlex ID: A5060015428

A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331

2020 · SM Castellino, SK Parsons, et al. · Klinische Pädiatrie · 4

Multi-modality Artificial Intelligence for Involved-Site Radiation Therapy: Clinical Target Volume Delineation in High-Risk Pediatric Hodgkin Lymphoma

2025 · X Tie, S A Milgrom, et al. · Klinische Pädiatrie

Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA)

2020 · RB Mailhot Vega, BS Hoppe, et al. · Klinische Pädiatrie

Works count: 3

Citation count: 4

H-index: 1

I10-index: